Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
69.09
+5.95 (+9.41%)
Streaming Delayed Price
Updated: 1:49 PM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
June 26, 2023
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles t
Via
MarketBeat
Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer
June 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks
June 23, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
AbTherx Announces License Agreement with Gilead
June 07, 2023
Via
ACCESSWIRE
Mount Gilead, NC Author Publishes Children's Book
May 17, 2023
Take In The Beauty Of Nature And Quiet The Outside World.
Via
PR Leap
Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan
June 22, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Alcoholic Hepatitis Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Durect Corporation, Novartis, Intercept Pharma, Gilead Sciences
June 16, 2023
Via
AB Newswire
Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023
June 14, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
2022 R&D Spending and Intensity Benchmarks
June 12, 2023
VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D...
Via
PRLog
Topics
Supply Chain
Exposures
Supply Chain
Is the Biotech Industry (IBB) Poised For A Major Breakout?
June 12, 2023
The current consolidation in the IBB signals a potential breakout might be looming as key moving averages have converged within a contracted price range.
Via
MarketBeat
Topics
ETFs
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
June 08, 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – June 8, 2023 – USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making...
Via
FinancialNewsMedia
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
June 06, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
June 05, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
June 05, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
June 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
June 05, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NASDAQ:RAIN),(NASDAQ:CNSP),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
COVID-19
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
June 01, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
May 26, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GILD),(NASDAQ:IMGN),(NASDAQ:DAWN),(NASDAQ:LEGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
May 26, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Present at Upcoming Investor Conference
May 25, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
May 18, 2023
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets.
Via
MarketBeat
Exposures
Product Safety
Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
May 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Appoints Cindy Perettie Executive Vice President of Kite
May 16, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation
May 15, 2023
From
Arcus Biosciences
Via
Business Wire
Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera
May 09, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference
May 04, 2023
Via
Investor Brand Network
Exposures
COVID-19
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
May 04, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
NanoViricides, Inc. (NYSE American: NNVC) Featured in Coverage of the Inaugural EF Hutton Global Conference
May 03, 2023
Via
Investor Brand Network
Exposures
COVID-19
Gilead Sciences to Present at Upcoming Investor Conferences
May 01, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences Announces First Quarter 2023 Financial Results
April 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
15
16
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.